X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7%
Thu, 14 Feb

NATCO PHARMA has announced its results for the quarter ended December 2018. Here is a detailed performance review of the same:

NATCO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-17*
3
Sep-18*
3
Dec-18*
QoQ ChangeYoY Change
Net SalesRs m5,6225,4355,5672.4%-1.0%
Other incomeRs m114400233-41.8%104.4%
TurnoverRs m5,7365,8355,800-0.6%1.1%
ExpensesRs m2,7573,2303,4837.8%26.3%
Gross profitRs m2,8652,2052,084-5.5%-27.3%
DepreciationRs m1722022072.5%20.3%
InterestRs m43506326.0%46.5%
Profit before taxRs m2,7642,3532,047-13.0%-25.9%
TaxRs m590537454-15.5%-23.1%
Profit after taxRs m2,1741,8161,593-12.3%-26.7%
Gross profit margin%51.040.637.4
Effective tax rate%21.322.822.2
Net profit margin%37.931.127.5
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter fell 1.0% on a year-on-year (YoY) basis. The expenses were up by 26.3% YoY during the same period.
  • The company's operating profit declined by 27.3% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 37.4% in 3QFY19 as against 51.0% in 3QFY18.
  • Depreciation charges increased by 20.3% and finance costs increased by 46.5% YoY, respectively.
  • Other income increased by 104.4% YoY during the quarter.
  • Net profit for the quarter declined by 26.7% YoY. Net profit margins during the quarter declined from 37.9% in 3QFY18 to 27.5% in 3QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 2.4% on a quarter-on-quarter (QoQ) basis. The expenses were up by 7.8% QoQ during the same period.
  • The company's operating profit declined by 5.5% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 37.4% in 3QFY19 as against 40.6% in 2QFY18.
  • Net profit for the quarter declined by 12.3% QoQ, while net profit margins declined from 31.1% in 2QFY18 to 27.5% in 3QFY19.

To see how NATCO PHARMA has performed over the last eight quarters, please visit here.

NATCO PHARMA Share Price Performance

Over the last one year, NATCO PHARMA share price has moved up from Rs 782.8 to Rs 608.0, registering a Loss of Rs 174.8 or around 22.3%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,757.6 (up 0.6%). Over the last one year it has moved down from 14,417.3 to 13,757.6, a gain of 660 points (down 4.6%).

Overall, the S&P BSE SENSEX is up 5.4% over the year.

Current Valuations

At the current price of Rs 608.0, the price to earnings (P/E) ratio of NATCO PHARMA stands at 12.3 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.3 times.

Equitymaster requests your view! Post a comment on "NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7%". Click here!

  

Related Views on News

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


May 24, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - ACTAVIS COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS